Late breaking abstract – New drug combination for the treatment of B Cell lymphoma

Around 40% of the patients with newly diagnosed diffuse large B-cell lymphoma are not cured with the current standard of care. In this MEDtalk, Gilles Salles presents the POLARIX Study where the addition of polatuzumab vedotin, an antibody drug that targets CD79b, was tested both in terms of efficacy and safety. The study showed significant benefits in terms of progression free survival, relapse or progression. Pola-R-CHP had a similar toxicity profile to R-CHOP.